Mō C-CAR031

Ko te C-CAR031 he rongoā ā-aunoa, he mea hanga ki te GPC3, e arotahi ana ki te chimeric antigen receptor T-Cell (CAR-T), e rangahauhia ana mō te rongoā i te HCC.

I whakaaturia ā-waha te ahunga whakamua o te rangahau o C-CAR031 i roto i te mate pukupuku hepatocellular (HCC) i te hui ā-tau a te American Society of Clinical Oncology (ASCO) i tū ki Chicago i te tau 2024.

Ngā Tikanga: Ko te whakamātautau tuatahi i roto i te tangata, he tuwhera-tapanga, e whakamahi ana i te hoahoa titration tere me te i3+3. Ko ngā tāngata GPC3+ HCC matatau i rahua i ngā maimoatanga pūnaha ≥ 1 raina i whiwhi i te werohanga kotahi o te C-CAR031 i muri i te lymphodepletion paerewa. Ko ngā pito whakamutunga matua ko te haumaru me te manawanui, ko ētahi ko te pharmacokinetics me te whai huatanga tuatahi. I whakatauria ngā pānga kino (AE) e te CTCAE 5.0, ā, i aromatawaihia te cytokine release syndrome (CRS) / te immune effector cell-associated neurotoxicity syndrome (ICANS) e ai ki ngā paearu ASTCT 2019. I aromatawaihia te urupare whāinga e te kairangahau e ai ki te RECIST 1.1.

Ngā Hua: I te 5 o Hānuere, 2024, e 24 ngā tāngata i whiwhi i te werohanga C-CAR031 i ngā taumata horopeta e 4 (DL). Ko ngā tāngata katoa he BCLC wāhanga C HCC, 83.3% (20/24) he metastasis i waho o te ate. Ko te maha toharite o ngā raina rongoā o mua he 3.5 (awhe 1-6), 23 (95.8%) ngā tāngata i whiwhi ICI (ngā aukati tirotiro ārai mate) me TKI (ngā aukati tyrosine kinase). I taea te aromatawai i ngā tāngata katoa mō te haumaru. Kāore he paitini whakawhāiti horopeta, ā, i kitea he ICANS. I kitea te CRS i roto i te 22 (91.7%) ngā tāngata me te 1 anake (4.2%) taumata (G) 3 CRS. Ko ngā AE ≥G3 tino noa ko te lymphocytopenia (100%), te neutropenia (70.8%), te thrombocytopenia (37.5%) me te whakanui transaminase (16.7%). Kotahi te tangata (4.2%) i pāngia e te G4 myelosuppression, ā, kotahi te tangata (4.2%) i pāngia e te G3 interstitial pneumonitis i te DL4 i puta mai i te G3 CRS. I taea te whakakore i ngā AE katoa. E 22 ngā tohu i taea te arotake mō te whai huatanga. I kitea te whakahekenga o te pukupuku i roto i te 90.9% o ngā tohu, ehara i te mea i roto i ngā whara o roto i te ate anake engari i waho atu hoki i te ate me te whakahekenga toharite o te 44.0% (awhe, 3.4%-94.4%). Ko te reiti whakahaere mate he 90.9%, ā, ko te reiti urupare whāinga (ORR) he 50.0% mō ngā tohu o ngā DL katoa. I roto i te DL4, ko te ORR he 57.1%.

Ngā Whakatau: I whakaatuhia e te rangahau he āhua haumaru ka taea te whakahaere, me te whakatenatena i te kaha ārai-puku o C-CAR031 i roto i ngā tūroro HCC matatau kua tino rongoatia.

I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.

Tau Waea：4008803716

Email：myimmnet@163.com

Ngā Tohutoro

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.Whakaaturanga-ASCO-2024-IR.pdf (astrazeneca.com)